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SHORT COMMUNICATION
Treatment interruptions and complications with two continuous hepatic
artery floxuridine infusion systems in colorectal liver metastases
C Fordy, D Burke, S Earlam, P Twort and TG Allen-Mersh
Department ofSurgery, Charing Cross and Westminster Medical School, Chelsea and Westminster Hospital, 369 Fulham Road,
London SWIO 9NH, UK.
Summary Continuous hepatic artery floxuridine infusion benefits patients with colorectal liver metastases.
Implanted infusion pumps are more expensive but may result in fewer treatment interruptions than when using
an external pump connected to a port. We have assessed device-related complications, treatment interruptions
and added nurse interventions in 95 patients undergoing a total of 959 treatment cycles via either implanted
pump (64 patients) or port (31 patients). Compared with the implanted pump, the port was associated with a
significant increase (P<0.003) in catheter blockage (24/31 vs 2/64 patients), treatment interruption (15/265 vs
12/694 treatments) and added nurse intervention (80/265 vs 20/694 treatments). Survival in patients with
colorectal liver metastases is limited and the complications of treatment should be kept to a minimum. An
implanted subcutaneous infusion pump offers the benefit of a 3-fold lower incidence of treatment interruption
and a 30-fold lower incidence of catheter blockage than when continuous infusion chemotherapy is given via
an external infusion device.
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Continuous hepatic artery floxuridine (FUdR) infusion pro-
duces the highest reported response (Dworkin and Allen-
Mersh, 1991) and a significant prolongation of survival in
treatment of colorectal liver metastases (Rougier et al., 1992;
Allen-Mersh et al., 1994).
FUdR is best administered to the liver by slow continuous
infusion since this results in a high first-pass extraction (Ens-
minger et al., 1978) which increases the advantage ofregional
administration (Ensminger and Gyves, 1984). Continuous
arterial administration of FUdR is via a cannula which can
be connected either to a subcutaneously implanted pump
(Niederhuber et al., 1984) or to a port which is accessed by a
needle connected to an external pump delivery system
(Figure 1).
The drawback of the implanted pump is that the purchase
price is roughly ten times greater than that of the port.
Against this, the port involves an external administration
device which might be more vulnerable to complications. To
assess whether the port system is an appropriate substitute
for the implanted pump we have compared the device-related
complications in colorectal liver metastasis patients being
treated by these two approaches.
Materials and methods
All patients with unresectable colorectal liver metastases
treated between January 1989 and January 1995 in one unit
were studied. Patients with disease confined to the liver were
entered into a randomised trial (Allen-Mersh et al., 1994)
where the purchase cost of implanted pumps was funded.
Patients with colorectal liver metastases who were not eligible
for this trial, either because of previous chemotherapy or the
presence of extrahepatic disease, received intrahepatic arterial
FUdR via a port connected to an external infusion pump
(Figure 1).
The arterial cannula was identical in both cases and was
similarly inserted into the hepatic artery as previously des-
cribed (Burke et al., 1995). The cannula was connected either
as an integral part of an Infusaid model 400 pump (Figure 1)
which was implanted subcutaneously in the right iliac fossa
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or to an Infusaport (Infusaid, Norwood, MA, USA) which




Figure 1 Implanted infusion pump (a) and port (b). The pump is
filled by percutaneous injection through the central membrane
into the drug reservoir. The second injection membrane situated
peripherally allows a flush injection directly through the catheter.
The port is connected to an external Baxter polyfusor device via
a right-angled needle which is inserted into the port for the
period ofdrug infusion. In both cases the catheter is inserted into
the hepatic artery via the gastroduodenal artery.Infusion devices in regonal chemotherapy of liver metastases
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On the 7th post-operative day, patients were commenced
on a continuous infusion of FUdR (0.2 mg kg-' body
weight 24 h-') for 14 days and this was repeated monthly.
During the interval between chemotherapy treatments, the
implanted pump was filled with heparinised saline (5000 units
of heparin dissolved in 50 ml of 0.9% saline) which was
continuously infused into the hepatic artery at a rate of
approximately 2 ml 24 h-'. FUdR was infused via the port at
a continuous rate (0.4 mg kg-' body weight 24 h-') for 7
days. The infusing device was attached to the port using a
22 G 'Gripper' Port-a-Cath needle (Pharmacia, St. Paul,
MN, USA), secured with Mepore tape and Tegaderm. Ports
were flushed with 20 ml of 0.9% saline and then 5000 units
of heparin dissolved in 10 ml of 0.9% saline at the end of the
chemotherapy treatment and not accessed again until the
beginning of the next month's course of treatment.
All treatments were administered on an out-patient basis.
Pump patients were seen at fortnightly intervals by chemo-
therapy nurses who noted any device-related complications
or interruptions to treatment. Port patients were seen mon-
thly by the nurses, and the patient's general practitioner or
practice nurse was taught how to flush the port and remove
the needle at the end of the 7 day chemotherapy course.
Added nurse interventions required because of device-
related complications during chemotherapy treatments were
recorded. Other reasons for added nurse intervention such as
drug-induced complications or symptoms of disease have not
been included.
Statistical analysis of differences between the two groups
has been performed using 2 x 2 contingency table analysis
with the chi-squared distribution and Fisher's exact test
where the numbers are small.
Results
Ninety-five patients receiving a total of 959 monthly FUdR
treatments were studied. Sixty-four received 694 treatments
via implanted pumps and 31 received 265 treatments via
external infusion devices connected to subcutaneous ports.
There were significantly more (P<0.001) added nurse
interventions with ports (80 added interventions, 30% of
treatments) compared with pumps (20, 2.9%). The device-
related complications necessitating these added nurse inter-
ventions are shown in Table I. It can be seen that the pattern
of complications was different between pumps and ports,
with significantly more (P<0.001) line occlusions in ports (24
line occlusions, 9% of treatments) than in pumps (2, 0.3%),
and needle displacement on ten occasions during infusion via
ports. In contrast, subcutaneous pocket haematoma or infec-
tion occurred in seven pump patients (1% of pump
treatments) but not in port patients).
Twenty-one of the 26 line occlusions were cleared by injec-
tion of a thrombolytic agent (ten by heparinised saline; seven
Table I The pattern of complications for subcutaneously implanted
pumps and ports was different. There was a significant increase in the
incidence of line occlusion and needle displacement with ports
(P<O.001) compared with pumps
Proportion of
treatments interrupted (%)
Pump (n = 694 Port (n = 265
Complication treatments) treatments)
Line occlusion 2 (0.3%) 24 (9%)
Needle disconnection - 10 (3.8%)
Pump failure 2 (0.3%)
Pocket infection 3 (0.4%) 0 (0%)
Pocket haematoma 4 (0.6%) 0 (0%)
Catheter displacement 4 (0.6%) 1 (0.4%)
Loose connection - 1 (0.4%)
Pump turned over 1 (0.1%) 0 (0%)
Burst polyfusor balloon - 1 (0.4%)
Air lock 0 (0%) 1 (0.4%)
by tissue plasminogen activator; four by urokinase). Five
ports developed cannula occlusions which could not be un-
blocked and treatment in these patients was continued by
systemic chemotherapy.
Device-related complications resulted in significantly more
(P = 0.003) interruptions to treatment via ports (15 interrup-
tions, 5.7% of treatments) compared with pumps (12, 1.7%).
Discussion
Avoidance of device-related complications is particularly
important in treatment of colorectal liver metastases since
this is a palliative treatment for patients with a limited
survival. As previously reported (Curley et al., 1993), we
found that device-related treatment interruptions were over
3-fold more frequent when treatment was by an external
device connected to a subcutaneous port compared with a
subcutaneously implanted pump. This was mainly caused by
the over 30-fold greater incidence of catheter blockage or
needle disconnection during infusion via ports. Hohn et al.
(1986> reported a 22% incidence of transient pump-related
occlusion which was abolished by increasing the heparin
dose, but this complication did not occur in our series.
Needle disconnection and port blockage were frequently
related: disconnection from the external device while the
needle remained within the port allowed blood under arterial
pressure to reflux up the arterial catheter tube into the port
chamber. If this was not noticed quickly and corrected by
heparin flushing thrombus blocked the port. Needle discon-
nection occurred for various reasons, for example one patient
got the infusion tubing tangled while getting out of her car.
A reduction in the risk of accidental disconnection might be
produced by limiting normal daily activities, or administering
chemotherapy as an in-patient, but this would impair quality
of survival and increase treatment cost.
Hoffman (1994) has suggested that line occlusions which
can be cleared by thrombolytic agents are of little sign-
ificance. Although we were able to clear 80% of line occl-
usions, these did produce treatment interruptions which in-
creased patient anxiety. In addition there was an extra treat-
ment cost from the nursing time and thrombolytics required
to flush the line. The greater potential for line occlusion
associated with ports increased patients' worry about whether
the treatment course would be completed.
As it is impractical to use the external device for longer
than 7 days a higher drug concentration is used in these
patients. This drug concentration may influence the catheter
blockage rate but, as the two regimens could not be made
identical, this could not be determined. The pattern of staff
involvement varied slightly between the two approaches.
Implanted pumps required a second routine oncology nurse
visit in each monthly cycle to fill the pump with heparinised
saline during the no-chemotherapy rest period, while general
practitioners or their practice nurses were required to help
with needle removal at the end of treatment in ports. This
difference in pattern of staff involvement could have cont-
ributed to the difference in complication rate.
Long-term hepatic artery infusion requires major surgery
for catheter insertion (Burke et al., 1995). Device-related
failure is disappointing for a patient who has been through
this surgery and is responding to treatment, but is unable to
continue because of catheter blockage. Many patients do not
have the physical stamina to undergo further major surgery
to replace a blocked hepatic arterial catheter. An implanted
subcutaneous infusion pump offers the benefits of a 3-fold
lower incidence of treatment interruption and a 30-fold lower
incidence of catheter blockage than when continuous infusion
chemotherapy is given via an external infusion device.
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